Navigation Links
Intellect Neurosciences Adds Two New Tau Programs to its Alzheimer's Disease Development Pipeline
Date:5/7/2012

NEW YORK, May 7, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.

(Logo: http://photos.prnewswire.com/prnh/20111214/NY22484LOGO)

Through an exclusive license obtained from Northwestern University, the company intends to develop and commercialize two proprietary antibodies, tauC3 and TOC-1, each of which targets certain abnormal forms of tau protein that are implicated in the nerve cell death that is characteristic to Alzheimer's disease and other tauopathies. The monoclonal antibodies were developed by Professor Lester Binder, Ph.D., the Abbott Laboratories, Duane and Susan Burnham Research Professor of Genetic and Molecular Medicine, at Northwestern University.

"Obtaining these two antibodies is a logical next step in positioning ourselves as a leader in Alzheimer's disease and other neurodegenerative disorders, as they add to our current approaches, which target tau proteins to develop new therapies for Alzheimer's disease. We intend to aggressively pursue the development of both antibodies, each of which has potential application in treating several diseases beyond Alzheimer's, including various orphan indications," said Dr. Daniel G. Chain, Chairman and CEO, Intellect Neurosciences. "Professor Binder has significantly advanced our understanding of Alzheimer's disease and related neurodegenerative diseases by generating these antibodies, which selectively target the most pathogenic forms of tau.  As a result, they have per
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
2. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
3. Intellectual Property Lawyer Available for Comment on Recent Supreme Court Ruling
4. Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum
5. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
6. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
7. iPierian Expands Leadership Team With Experienced Business Development and Intellectual Property Executives
8. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
9. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
10. BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
11. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... May 21, 2015 Tunnell Consulting, ... the firm as senior statistician and Principal, a position ... experience in the management and analysis of complex and ... chemical industries. , “We’re delighted to have Julia join ... data analytics,” said Dr. Philippe Cini, Group Vice President ...
(Date:5/20/2015)... MECHANICSBURG, Pa. , May 20, 2015 /PRNewswire/ ... announced that the Federal Trade Commission granted early ... (HSR) Antitrust Improvements Act of 1976, as amended, ... by MJ Acquisition Corporation, a joint venture that ... XII, L.P. As previously announced, MJ ...
(Date:5/20/2015)... 20, 2015  Haemonetics Corporation (NYSE: HAE ) ... CEO, will present at The Jefferies 2015 Global Healthcare ... June 1 st , 2015 at 8:30am Eastern time.  ... presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated to ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Surface Logix today announced positive,results in ... SLx-4090 in,dyslipidemia (high cholesterol and triglyceride levels ... 2a study in 24,patients with dyslipidemia demonstrated ... triglycerides and LDL-cholesterol,and was well tolerated. The ...
... Edwards Lifesciences,Corporation (NYSE: EW ), the world leader ... has received conditional approval from the U.S.,Food and Drug ... pivotal,clinical trial of the Edwards SAPIEN transcatheter aortic heart ... transapical,delivery system to the trial, and also granted permission ...
... ) consolidated net earnings for the quarter ended December ... diluted share compared,with $18.7 million or $.47 per diluted ... six months ended December 31, 2007, Techne,s consolidated,net earnings ... share,compared with $38.3 million or $0.97 per diluted share ...
Cached Biology Technology:Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 2Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 3Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 4Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 2Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 3Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 2Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 3Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 4Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 5Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 6Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 7
(Date:4/27/2015)... 27, 2015  For more than four decades, AUVSI,s ... been the premier worldwide event for the unmanned land, ... must-attend event for any local, national, or trade news ... commercial markets and current applications of unmanned technologies. The ... projected $48 billion industry, and how it will soon ...
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... CLEMSON The National Science Foundation (NSF) has awarded ... Engineering (CBIOE) at Clemson University for the development of ... causes, progression and treatment of breast cancer. The ... based on inkjet printing and will allow the creation ...
... Over the last forty years, Shigetada Nakanishi has unraveled ... the human nervous system. His work has created ... Today at 2.30 pm he will receive the Gruber ... Diego. In the 2007 Gruber Lecture he will ...
... the Journal of Proteome Research, authored by researchers ... Rosetta Inpharmatics LLC, CXR Biosciences Ltd, the Cancer ... and enhanced analytic power of the combination of ... microarray analysis methods of Genomatix Software GmbH., The ...
Cached Biology News:Breast cancer research and inkjet tissue printing get NSF boost 2Shigetada Nakanishi receives $500,000 Gruber Neuroscience Prize 2
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
... Thermo's Wellwash AC is the easiest ... and is provided with liquid level ... bottles. The integrated orbital shaker and ... excellent washing performance. The big bottle ...
Biology Products: